PML on Tecfidera - the MHRA response

Following the death due to PML last year of a German MSer who had been taking Tecfidera for over 4 years, and been lymphopenic for over 3, the MHRA has now issued a new "Drug safety update".

Your chances of developing an opportunistic infectious disease (such as PML in people who are JCV+) will increase if you have chronic lymphopenia.

The Barts-MS Guideline for people on Tecfidera is as follows:

BartsMS Clinical Guidance Tecfidera from Klaus Schmierer

Labels: ,